BioAtla, Inc.
BCABNasdaq
$3.95
↓ -1.0%Jul 17 close · end-of-day
Price
1Y↓ -79.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.9M
Enterprise Value
$4.0M
P/E
0.5
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$68.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-183.8%
ROIC
—
Debt / Equity
—
Net Cash
$2.0M
Return 1Y
-78.7%
Company profile
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate.
- CEO
- Jay M. Short
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- California
- Website
- bioatla.com
Management & directors
- Short Jay M PhdChief Executive Officer
- Sievers EricChief Medical Officer
- Vasquez ChristianChief Financial Officer
- Waldron Richard AFormer Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
BCAB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$4.22↓ -67.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $300,000.00 | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$30.1M | -$96.4M | -$108.1M | -$129.7M | -$73.9M | -$59.3M |
| Net income | -$35.9M | -$95.4M | -$106.5M | $123.5M | $69.8M | $59.6M |
| Diluted EPS | — | -$2.76 | -$2.74 | -$2.58 | -$1.44 | -$1.01 |
| Operating cash flow | -$36.3M | -$62.2M | -$90.4M | -$104.0M | -$71.9M | -$48.2M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -32146.7% | — | — | — | — |
| Net margin | — | -31800.7% | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$22.0M | -$11.3M | -$16.2M | -$17.6M | -$18.6M | -$13.8M | -$9.3M | -$9.3M |
| Net income | -$21.1M | -$10.6M | $124.7M | -$15.3M | -$18.7M | -$15.8M | $109.4M | -$6.3M |
| Diluted EPS | -$0.44 | -$0.22 | -$0.30 | -$13.16 | -$0.32 | -$0.27 | $12.74 | -$4.22 |
| Operating cash flow | -$19.2M | -$5.1M | -$16.8M | -$16.3M | -$14.1M | -$9.9M | -$7.9M | -$5.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 18, 2026
Mar 31, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-31 | SHORT JAY M PHD· Chief Executive Officer | Tax withholding | 259 | $3.93 | $1,017.87 | filing |
| 2026-05-31 | Sievers Eric· Chief Medical Officer | Tax withholding | 134 | $3.93 | $526.62 | filing |
| 2026-05-31 | Vasquez Christian· Chief Financial Officer | Tax withholding | 82 | $3.93 | $322.26 | filing |
| 2026-03-12 | SHORT JAY M PHD· Chief Executive Officer | Tax withholding | 639 | $0.17 | $107.35 | filing |
| 2026-03-11 | Sievers Eric· Chief Medical Officer | Tax withholding | 360 | $0.17 | $60.84 | filing |
| 2026-03-11 | Vasquez Christian· Chief Financial Officer | Tax withholding | 175 | $0.17 | $29.58 | filing |
| 2026-03-11 | SHORT JAY M PHD· Chief Executive Officer | Award | 430,000 | $0.00 | $0.00 | filing |
| 2026-03-10 | Sievers Eric· Chief Medical Officer | Award | 240,000 | $0.00 | $0.00 | filing |
| 2026-03-10 | Vasquez Christian· Chief Financial Officer | Award | 240,000 | $0.00 | $0.00 | filing |
| 2026-02-28 | SHORT JAY M PHD· Chief Executive Officer | Tax withholding | 7,728 | $0.25 | $1,908.82 | filing |
| 2026-02-28 | Sievers Eric· Chief Medical Officer | Tax withholding | 3,140 | $0.25 | $775.58 | filing |
| 2026-02-28 | WALDRON RICHARD A· Former Chief Financial Officer | Tax withholding | 2,729 | $0.25 | $674.06 | filing |
| 2026-02-28 | Vasquez Christian· Chief Financial Officer | Tax withholding | 1,802 | $0.25 | $445.09 | filing |
| 2025-11-30 | SHORT JAY M PHD· Chief Executive Officer | Tax withholding | 6,347 | $0.90 | $5,737.69 | filing |
| 2025-11-30 | Sievers Eric· Chief Medical Officer | Tax withholding | 2,729 | $0.90 | $2,467.02 | filing |
| 2025-11-30 | WALDRON RICHARD A· Chief Financial Officer | Tax withholding | 2,371 | $0.90 | $2,143.38 | filing |
| 2025-11-30 | Vasquez Christian· See Remarks | Tax withholding | 1,566 | $0.90 | $1,415.66 | filing |
| 2025-08-31 | SHORT JAY M PHD· Chief Executive Officer | Tax withholding | 6,347 | $0.46 | $2,891.06 | filing |
| 2025-08-31 | Sievers Eric· Chief Medical Officer | Tax withholding | 2,729 | $0.46 | $1,243.06 | filing |
| 2025-08-31 | WALDRON RICHARD A· Chief Financial Officer | Tax withholding | 2,371 | $0.46 | $1,079.99 | filing |
| 2025-08-31 | Vasquez Christian· See Remarks | Tax withholding | 1,566 | $0.46 | $713.31 | filing |
| 2025-06-18 | MCBRINN SYLVIA | Award | 23,500 | $0.00 | $0.00 | filing |
| 2025-06-18 | Smith Scott Andrew | Award | 23,500 | $0.00 | $0.00 | filing |
| 2025-06-18 | Moran Susan | Award | 23,500 | $0.00 | $0.00 | filing |
| 2025-06-18 | Williams Eddie | Award | 23,500 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.